About the Project

The goal of this study is to build a better understanding of how widespread

COVID-19 is in Canada among our most vulnerable and high-risk populations, as well as the effectiveness and safety of currently approved COVID-19 vaccines.

Long-term care homes across the world have been gravely impacted by COVID-19. In Canada, approximately 60% of the deaths related to COVID-19 were in long-term care homes. Residents in long-term care homes are particularly vulnerable to COVID-19, given their advanced age, reduced immune system capacity, and multiple underlying health conditions. Individuals who work in long-term care homes also face an increased risk of exposure to COVID-19.

The Government of Canada, via its COVID-19 Immunity Task Force (CITF), has funded several studies  - spanning Halifax to Vancouver - to investigate various aspects of immunity and people’s response to vaccines within long-term care homes.

This project includes long-term care home residents and workers in Québec, Ontario and British Columbia.

The research team is hoping to collect dried blood spot samples from nearly 8,000 long-term care residents and workers to look for the presence of antibodies against COVID-19. Findings from this research will show how various immunity factors, such as antibodies, react to COVID-19 and to the COVID-19 vaccines.